Theranos adds John McChesney and Tali Mackay
Tuesday, December 13, 2016
Theranos has announced that key roles have been filled in the company’s executive ranks, with the naming of John McChesney to senior vice president of operations and Tali Mackay to senior vice president of corporate communications and investor relations, as well as the promotion of David Taylor to the role of general counsel. Dr. Gregory J. Tsongalis was appointed to the company’s Scientific and Medical Advisory Board (SMAB).
“One of my primary areas of focus this year has been the establishment of our new leadership team,” said Theranos CEO Elizabeth Holmes. “I am proud to welcome these seasoned executives, and am humbled by the passion and commitment of the team working to realize our mission of accessible, affordable health information.”
John McChesney joins the company with medical device manufacturing expertise, having served in roles of increasing responsibility at GenapSys, Thermo Fisher Scientific and Medtronic. He has extensive experience leading teams through periods of change, including acquisitions, quality system deployments, high growth, development of manufacturing centers of excellence, and building global supply chains. He is a graduate of the University of California, San Diego.
Tali Mackay brings high-stakes communications expertise, including crisis communications and issues management, corporate branding and reputation, and mergers and acquisitions. Her experience encompasses roles at Genentech, Baxter, and global public relations firms. Mackay holds a B.A. from the University of California, Berkeley, and an M.S.N. from San Francisco State University. She was a registered nurse, with clinical specialties in neurosurgery and hospice.
David Taylor joined Theranos as senior litigation counsel in May and thereafter served as acting general counsel. Taylor previously practiced with Munger, Tolles & Olson LLP and Williams & Connolly LLP and has over 10 years of experience in complex litigation. He holds a J.D. from the University of California, Berkeley and a B.A. from Williams College.
Dr. Gregory J. Tsongalis has held several clinical and academic positions and has been a member of numerous corporate scientific advisory boards. He received his Ph.D. in pathology from the University of Medicine and Dentistry of New Jersey (now Rutgers University) and completed his postdoctoral training in molecular oncology and clinical chemistry/molecular pathology at the University of North Carolina at Chapel Hill. His area of expertise is in clinical molecular diagnostic applications and technology development, and he conducts research in the pathogenesis of human cancers, personalized medicine, and disruptive technologies. He has served on numerous committees of the AACC, ASIP, FASEB, and AMP, where he is a past president.